Evidence map›Paper›PMID 40894277›Full record

ArticleCurrent urology2025

Next-generation sequencing identifies the mutational signature of double primary and metastatic malignancies: A case report.

Shiying Tang, Yixiao Deng, Yinan Yan, Jie Bai, Huiying He, Shudong Zhang, Jie Yang, Min Qiu, Xiaojun Tian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shiying TangDepartment of Urology, Peking University Third Hospital, Beijing, China.
Yixiao DengYuceBio Technology Co., Ltd., Shenzhen, China.
Yinan YanYuceBio Technology Co., Ltd., Shenzhen, China.
Jie BaiDepartment of Thoracic surgery, Peking University Third Hospital, Beijing, China.
Huiying HeDepartment of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing, China.
Shudong ZhangDepartment of Urology, Peking University Third Hospital, Beijing, China.
Jie YangYuceBio Technology Co., Ltd., Shenzhen, China.
Min QiuDepartment of Urology, Peking University Third Hospital, Beijing, China.
Xiaojun TianDepartment of Urology, Peking University Third Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the case of a 59-year-old Chinese man diagnosed with stage III clear cell renal cell carcinoma who developed 2 suspicious lung lesions 5 years after follow-up. Pathological evaluation revealed 2 distinct types of cancer: lung adenocarcinoma in situ and clear cell renal carcinoma with lung metastasis. Lung tissue samples were sequenced using a panel of 1267 cancer-related genes. The analysis revealed completely different molecular profiles between the 2 lung lesions and similar clonal mutations in the superior lingular lobe and kidney. This indicates multiple metachronous primary tumors.

Indexed as

Adenocarcinoma in situ of lungClear cell renal cell carcinomaMAP2K1 geneMultiple primary tumorsNext-generation sequencingVHL gene

Identifiers

PMID40894277
PMCPMC12398379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.